TABLE 3.
Univariate and multivariate logistic regression analyses exploring independent predictors of positive pathological response to neoadjuvant chemohormonal therapy.
| Variables | Positive pathological responses | ||||
|---|---|---|---|---|---|
| Univariate | Multivariate | ||||
| OR (95% CI) | p‐value | β | OR (95% CI) | p‐value | |
| Age (years) | 1.000 (0.944–1.059) | 0.990 | |||
| BMI (kg/m2) | 1.108 (0.997–1.232) | 0.056 | |||
| Initial PSA at diagnosis (ng/mL) | 0.947 (0.909–0.986) | 0.008 | −0.096 | 0.909 (0.847–0.975) | 0.008 |
| ISUP grading group of biopsy specimens | |||||
| 4 versus 3 | 1.048 (0.436–2.518) | 0.917 | |||
| 5 versus 3 | 0.602 (0.206–1.757) | 0.353 | |||
| EAU clinical T stage | |||||
| 3a versus 2c | 0.552 (0.139–2.197) | 0.399 | |||
| 3b versus 2c | 0.613 (0.157–0.239) | 0.482 | |||
| 4 versus 2c | 1.000 (0.156–6.420) | 1.000 | |||
| PI‐RADS v2 score | |||||
| 4 versus 3 | 0.585 (0.158–2.161) | 0.421 | |||
| 5 versus 3 | 1.000 (0.265–3.769) | 1.000 | |||
| PPF radiomics signature | 2.718 (1.866–3.960) | <0.001 | 0.916 | 2.499 (1.545–4.042) | <0.001 |
| Intratumoral radiomics signature | 2.718 (1.782–4.145) | <0.001 | 0.708 | 2.030 (1.284–3.209) | 0.002 |
Abbreviations: BMI, body mass index; CI, confidence interval; ISUP, International Society of Urological Pathology; OR, odds ratio; PI‐RADS v2, Prostate Imaging Reporting and Data System version 2; PPF, periprostatic fat; PSA, prostate‐specific antigen.